Abstract #2093

Yung A, Yuan Q, Jackson E, Mahankali S

Two threshold-based, whole tumor ROI analysis algorithms based on ipsilateral, pre-contrast baseline signal intensity, and contralateral, pre-contrast mode-based signal intensity, are used to analyze serial DCE-MRI data following the oral administration of a receptor tyrosine kinase inhibitor in six patients with Glioblastoma Multiforme. The basis for this comparison is that user-defined, whole tumor ROIs are unable to evaluate tumor heterogeneity in malignant lesions and thus may be insensitive to drug action. Data demonstrate varied response outcomes encountered with the different techniques and highlight the need to develop standardized approaches to measurement particularly essential in this era of multi-center trials.